The question is no longer if, but when. Last week’s executive order from President Donald Trump, accelerating the rescheduling of cannabis from Schedule I to Schedule III, represents far more than a minor regulatory adjustment—it is a calculated political rehearsal paving the way for full federal legalization by 2026.
A historic pivot for the American cannabis industry is now clearly in view.
Moving cannabis out of the same category as heroin and acknowledging its medical use is symbolically revolutionary in itself. The most immediate commercial impact is expected to be the dismantling of the industry-crippling Section 280E tax burden. Once lifted, cannabis businesses will be able to deduct ordinary expenses like any other legal enterprise, potentially unleashing explosive profit margin growth. Simultaneously, the cautious stance of banks and financial institutions is likely to thaw rapidly, injecting unprecedented capital into the sector. These moves collectively clear fundamental obstacles for a unified national market.
Looking back at Trump’s October post on Truth Social tentatively supporting Medicare coverage for medical marijuana, followed by this decisive executive action, a policy roadmap is coming into focus. Politically, championing legalization could convert a broad base of supporters—particularly younger voters—into ballots, while generating substantial tax revenue, an allure both parties may find hard to resist. Public opinion is already aligned: nearly two-thirds of American adults support legalization, while 40 states have already passed medical or recreational cannabis laws, creating a de facto reality of local markets encircling federal prohibition. There is compelling reason to forecast that 2026 may well be the year federal legislation ends the nationwide cannabis ban.
Keen-sensed industry giants are already moving. Canadian powerhouse Tilray Brands (TLRY) swiftly announced the formation of a U.S. subsidiary to secure a beachhead. While other major players like Aurora Cannabis (ACB) and Canopy Growth (CGC) remain publicly quiet for now, their leadership is undoubtedly engaged in urgent strategic planning for a full-scale push into the U.S. market. With the shackles of Section 280E potentially removed, the profitability curves for these companies could steepen dramatically. Analysts note that the current rescheduling action has already infused cannabis equities with powerful momentum; should full legalization arrive, the entire sector could experience a tsunami of revaluation.
The trajectory from 2025 rescheduling to predicted 2026 legalization is rapidly sketching the framework for an entirely new legal industry in America. This promises not only the consolidation and expansion of existing state markets but also the explosion of international trade, derivative product development, and branded consumer goods across the entire supply chain. Once regulatory barriers fall, a flood of capital will enter, transforming the industry from its current fragmented, state-limited operational model into a unified, efficient, and highly capitalized national—and ultimately global—enterprise.
In summary, the Trump administration’s rescheduling order is not the finish line, but the starting pistol. It officially marks the beginning of the countdown to federal cannabis legalization in the United States. In 2026, we may very well witness the final breaking of an industry chain that has been locked for decades—and the dawn of a new era.
